Daratumumab for Multiple myeloma

Inclusion criteria

• {"criterion_text":"- Patient is, in the investigator’s opinion, willing and able to comply with the protocol requirements.\n- Female childbearing potential patient (FCBP) criteria: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female patient is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: • Is not a female of childbearing potential (FNCBP) OR • Is a FCBP and ✓ She understands the potential teratogenic risk to the unborn child. ✓ She understands the need for effective contraception, without interruption, 28 days before starting study treatment, throughout the entire duration of study treatment, during dose interruptions and for at least 3 months after the last dose of study treatment. ✓ She understands and agrees to inform the Investigator if a change or stop of method of contraception is needed. ✓ She must be capable of complying with effective contraceptive measures. ✓ She is informed and understands the potential consequences of pregnancy and the need to notify the Investigator if there is a risk of pregnancy. ✓ She understands the need to commence study treatment as soon as it is dispensed following a negative pregnancy test. ✓ She understands and accepts the need to undergo pregnancy testing based on the frequency outlined in this plan and in the Informed Consent. ✓ She acknowledges she understands the hazards study drugs can cause to an unborn fetus and the necessary precautions associated with the use of study drugs. ✓ She understands and accepts the need to undergo pregnancy testing based on the frequency outlined in this plan and in the Informed Consent. ✓ She acknowledges she understands the hazards study drugs can cause to an unborn fetus and the necessary precautions associated with the use of study drugs. The Investigator must ensure that a FCBP: Complies with the conditions of the pregnancy prevention plan, including confirmation that she has an adequate level of understanding. Acknowledges the aforementioned requirements. A FCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 24 hours before the first dose of study drug(s). Non-childbearing potential is defined as follows (by other than medical reasons): o Has not achieved menarche at some point. o Has undergone a hysterectomy or bilateral oophorectomy. o Has been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has not had menses at any time in the preceding 24 consecutive months).\n- Male patient: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male patient is eligible to participate if he agrees to the following during dose interruptions and for at least 3 months following the last dose of iberdomide to allow for clearance of any altered sperm: • Understand the potential teratogenic risk if engaged in sexual activity with a pregnant female or a FCBP. • Understand the need for the use of a condom even if he has had a vasectomy, if engaged in sexual activity with a pregnant female or a FCBP. • Understand the potential teratogenic risk if the subject donates semen or sperm. • Understand that the effects on fertility are currently unknown, therefore all family planning options and/or alternatives should be thoroughly discussed with the study doctor prior to receiving study drugs.\n- All prior treatment-related toxicities (defined by National Cancer Institute - Common Toxicity Criteria for Adverse Events), version 5.0 must be ≤ Grade 1 at the time of enrolment except for alopecia.\n- Patient must be able to understand the study procedures.\n- Patient has given voluntary written informed consent before performance of any study-related procedure nor part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.\n- Newly diagnosed multiple myeloma patient ≥ 65 years or younger but non-transplant eligible who requires start active treatment according to the IMWG published in 2014.\n- Patient must have a measurable secretory disease defined as either serum monoclonal protein of ≥ 0,5 g/dl or urine monoclonal (light chain) protein ≥ 200 mg/24 h. For patients whose disease is only measurable by serum FLC, the involved FLC should be ≥ 10mg/dL (100 mg/L), with an abnormal serum FLC ratio.\n- Patient is defined as non-frail or frail using the modified-IMWG scale. Frailty score according to the modified-IMWG scale will be collected before starting the treatment in order to ensure 30% of the patients are frail.\n- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.\n- Patient must be ≥ 18 years of age.\n- Patient must have adequate organ function, defined as follows (see Table 3 in the protocol)."}

Exclusion criteria

• {"criterion_text":"- Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), plasma cell leukemia or active POEMS syndrome at the time of screening.\n- Patient has a known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to iberdomide or drugs chemically related to iberdomide, or any of the excipients contained in the formulation of the study treatment.\n- Patient has a known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to daratumumab or drugs chemically related to daratumumab, or any of the excipients contained in the formulation of the study treatment.\n- Participant has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to other monoclonal antibodies.\n- Patient has a known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to dexamethasone or drugs chemically related to dexamethasone, or any of the excipients contained in the formulation of the study treatment.\n- Major surgery (except kyphoplasty) ≤ 4 weeks prior to initiating protocol therapy.\n- Patient has peripheral neuropathy or neuropathic pain grade ≥2, as defined by the National Cancer Institute Terminology Criteria for Adverse Events (NCI CTC AE) Version 5.0.\n- Patient evidence of cardiovascular risk including any of the following: • QTcF interval QTcF > 480 msec (the QT interval values must be corrected for heart rate by Fridericia’s formula [QTcF]). • Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd degree atrioventricular (AV) block. • History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening. • Class III or IV heart failure as defined by the New York Heart Association functional classification system [NYHA, 1994]. • Uncontrolled hypertension, defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment.\n- Patient has current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria.\n- Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect patient’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil inclusion criteria.\n- Evidence of active mucosal or internal bleeding.\n- Patient has had clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS multiple myeloma.\n- Any serious medical condition or psychiatric illness that would interfere in understanding of the informed consent form.\n- Uncontrolled endocrine diseases (i.e. diabetes mellitus, hypothyroidism or hyperthyroidism) (i.e. requiring relevant changes in medication within the last month, or hospital admission within the last 3 months).\n- Patients with acute diffuse infiltrative pulmonary disease and/or pericardial disease.\n- Patients with severe chronic obstructive pulmonary disease (COPD) or asthma with forced expiratory volume in the first minute (FEV1) less than 50%.\n- History of interstitial lung disease or ongoing interstitial lung disease.\n- Patient has an active infection requiring antibiotic, antiviral, or antifungal treatment.\n- Participant has known HIV infection.\n- Patient has presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study treatment.\n- Patient has positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. Note: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.\n- Patient has invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction.\n- Any serious medical condition that places the subject at an unacceptable risk if he or she participates in this study; subjects with conditions requiring chronic steroid or immunosuppressive treatment, such as rheumatoid arthritis, multiple sclerosis and lupus, that likely need additional steroid or immunosuppressive treatments in addition to the study treatment.\n- Pregnant or breastfeeding females.\n- Patient is simultaneously enrolled in other interventional clinical trial.\n- Received plasmapheresis within 7 days prior to the first dose of study drug.\n- Patient has received prior radiotherapy within 2 weeks of start of study therapy. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.\n- Patients has used any anti-myeloma drug therapy, except for steroid pulses in case of emergency (40 mg of dexamethasone for 4 days), the administration of bisphosphonates or antialgic radiotherapy or due to the presence of plasmacytomas requiring some emergency."}

Primary endpoints

• {"endpoint_text":"- Overall Response Rate (ORR) with the different responses categories and especially the Complete Response Rate (CRR), defined as the percentage of participants with a confirmed complete response (CR) or better (stringent complete response (CR, sCR).","definition_or_measurement_approach":"Defined as the percentage of participants with a confirmed complete response (CR) or better (stringent complete response (CR, sCR)."}

Secondary endpoints

• {"endpoint_text":"- Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative by next-generation flow cytometry (NGF), PET/CT, and mass spectrometry. Analysis of MRD will be done by NGF according to International Myeloma Working Group (IMWG).","definition_or_measurement_approach":"MRD negativity rate defined as percentage MRD negative by NGF, PET/CT, and mass spectrometry; analysis by NGF per IMWG."}
• {"endpoint_text":"- Progression-Free Survival (PFS), defined as the time from the start date of the study treatment until the earliest date of documented disease progression or death due to any cause.","definition_or_measurement_approach":"PFS defined as time from start of study treatment to earliest documented disease progression or death from any cause."}
• {"endpoint_text":"- Overall Survival (OS), defined as the time from the start date of the study treatment until the date of death due to any cause.","definition_or_measurement_approach":"OS defined as time from start of study treatment until date of death due to any cause."}
• {"endpoint_text":"- Determine the relative distribution and immunophenotype of myeloid suppresser cells, monocytes and macrophages, antigen presenting cells, NK, B and T cells from baseline onto treatment, remission and disease progression.","definition_or_measurement_approach":"Flow cytometry/immunophenotyping to characterise relative distribution and immunophenotype from baseline through treatment/remission/progression (methodology as per protocol)."}
• {"endpoint_text":"- EQ-5D/5L, QLQ-C30 and MY20 questionnaires, at baseline and at months 4, 8, 12, 18, and 24.","definition_or_measurement_approach":"Patient-reported outcome measures collected at baseline and months 4, 8, 12, 18, 24 using EQ-5D/5L, QLQ-C30 and MY20 questionnaires."}
• {"endpoint_text":"- Incidence of deaths and primary cause of death. - Data for vital signs. - Incidence of adverse events (AEs). - Percentage of patients discontinuing therapy due to AEs. - Percentage of patients requiring dose modifications. - Changes in laboratory analytes from the hematology and blood chemistry panel.","definition_or_measurement_approach":"Safety endpoints: collection of deaths and causes, vital signs, AEs per NCI CTCAE v5.0, discontinuations for AEs, dose modifications, and laboratory changes (hematology and chemistry panels) as per protocol schedules."}
• {"endpoint_text":"- Time to Progression (TTP).","definition_or_measurement_approach":"TTP defined per protocol (time from inclusion/start of treatment to documented progression)."}
• {"endpoint_text":"- Time from start therapy to second disease progression or to the moment in which the third line of therapy starts: PFS2.","definition_or_measurement_approach":"PFS2 defined as time from start of therapy to second progression or start of third-line therapy."}
• {"endpoint_text":"- Overall survival (OS).","definition_or_measurement_approach":"OS defined as time from start of study treatment until date of death due to any cause (duplicate endpoint listed in secondary endpoints)."}

Spain

Earliest CTIS Part Ii Submission Date

18-11-2024

Latest Decision Or Authorization Date

20-11-2024

Processing Time Days

2

Number Of Sites

16

Number Of Participants

140

Primary sponsor

Full Name

Fundacion PETHEMA

Organisation Type

Patient organisation/association

Country Of Registered Address

Spain